The estimated Net Worth of Jessica Fees is at least 285 千$ dollars as of 1 August 2023. Ms. Fees owns over 9,434 units of Surface Oncology Inc stock worth over 109,049$ and over the last 6 years she sold SURF stock worth over 175,723$. In addition, she makes 0$ as Principal Financial Officer、 Principal Accounting Officer、 Senior Vice President、 Finance and Treasurer at Surface Oncology Inc.
Jessica has made over 9 trades of the Surface Oncology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 9,434 units of SURF stock worth 8,868$ on 1 August 2023.
The largest trade she's ever made was selling 19,854 units of Surface Oncology Inc stock on 21 July 2021 worth over 121,109$. On average, Jessica trades about 3,097 units every 104 days since 2019. As of 1 August 2023 she still owns at least 101,915 units of Surface Oncology Inc stock.
You can see the complete history of Ms. Fees stock trades at the bottom of the page.
Jessica Fees serves as Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer of the Company. She has served as our principal financial officer and principal accounting officer since December 2018, and as Senior Vice President, Finance since November 2018. Ms. Fees joined the Company in September 2015 as the Company’s Director of Finance. Prior to joining us, Ms. Fees served as President of Glide Associates LLC from January 2011 to March 2016. Prior to that, she worked at Tokai Pharmaceuticals, Inc. from August 2005 to June 2011. Ms. Fees began her career at Arthur Andersen LLP. Ms. Fees has a B.A. from The College of the Holy Cross and earned her CPA in Massachusetts.
Jessica Fees is 48, she's been the Principal Financial Officer、 Principal Accounting Officer、 Senior Vice President、 Finance and Treasurer of Surface Oncology Inc since 2018. There are 8 older and 7 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.
Jessica's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Surface Oncology Inc have traded over 69,198,912$ worth of Surface Oncology Inc stock and bought 2,836,996 units worth 42,496,090$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of 156,856$. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth 6,619$.
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Surface Oncology Inc executives and other stock owners filed with the SEC include: